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Abstract
Global AIDS policy still treats HIV as an exceptional case, abstracting from the context in which infection
occurs. Policy is based on a simplistic theory of HIV causation, and evaluated using outdated tools of health
economics. Recent calls for a health systems strategy – preventing and treating HIV within a programme of
comprehensive health care – have not yet influenced the silo approach of AIDS policy.
Evidence continues to accumulate, showing that multiple factors, such as malnutrition, malaria and
helminthes, increase the risk of sexual and vertical transmission of HIV. Moreover, complementary
interventions that reduce viral load, improve immune response, and interrupt pathways of transmission could
increase the effectiveness of antiretroviral drugs and other tools of AIDS policy.
In health economics, the omission of estimates of increasing returns generated by disease or treatment
synergies biases cost-effectiveness analysis against multiple, yet inexpensive, interventions. Current tools of
cost-effectiveness analysis only identify local maxima in a complex landscape, and can play, at best, a marginal
role in the epidemic, especially where it is already generalized.
Cost-effectiveness analyses for HIV that are based on the wrong epidemiological model can generate Type III
errors: we get precise answers to the wrong questions about how to intervene. To control the epidemic, AIDS
policy needs to utilize an epidemiological model that reflects the interactions of biological as well as
behavioural variables that determine the course of HIV epidemics around the world. Cost-effectiveness
analysis can benefit from using economic concepts of externalities and increasing returns to incorporate
disease interactions and beneficial treatment spillovers for coinfections in HIV-prevention policy.
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Abstract
Global AIDS policy still treats HIV as an exceptional case, abstracting from the context in which
infection occurs. Policy is based on a simplistic theory of HIV causation, and evaluated using
outdated tools of health economics. Recent calls for a health systems strategy – preventing and
treating HIV within a programme of comprehensive health care – have not yet influenced the silo
approach of AIDS policy.
Evidence continues to accumulate, showing that multiple factors, such as malnutrition, malaria and
helminthes, increase the risk of sexual and vertical transmission of HIV. Moreover, complementary
interventions that reduce viral load, improve immune response, and interrupt pathways of
transmission could increase the effectiveness of antiretroviral drugs and other tools of AIDS policy.
In health economics, the omission of estimates of increasing returns generated by disease or
treatment synergies biases cost-effectiveness analysis against multiple, yet inexpensive,
interventions. Current tools of cost-effectiveness analysis only identify local maxima in a complex
landscape, and can play, at best, a marginal role in the epidemic, especially where it is already
generalized.
Cost-effectiveness analyses for HIV that are based on the wrong epidemiological model can
generate Type III errors: we get precise answers to the wrong questions about how to intervene.
To control the epidemic, AIDS policy needs to utilize an epidemiological model that reflects the
interactions of biological as well as behavioural variables that determine the course of HIV
epidemics around the world. Cost-effectiveness analysis can benefit from using economic concepts
of externalities and increasing returns to incorporate disease interactions and beneficial treatment
spillovers for coinfections in HIV-prevention policy.
Introduction
Over the past 25 years, global AIDS prevention policy has
remained largely isolated from mainstream epidemiol-
ogy, which recognizes that epidemics arise from the inter-
action of multiple biological characteristics of the host,
pathogen and environment. The result has been an
implicit (and often explicit) theory of HIV causation that
treats AIDS as a special case, unrelated to the context of
malnutrition or parasitic and infectious disease in which
the epidemic flourishes.
Health economics uses tools such as cost-effectiveness
analysis to evaluate alternative interventions for preven-
tion and treatment. Just as AIDS policy is isolated from the
conventional understanding of disease interactions,
health economics has remained isolated from an expand-
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ing toolkit in other fields of economics that recognize
interaction and incorporate externalities and increasing
returns. Thus it is poorly equipped to evaluate interven-
tions that have spillover benefits, such as when treating
one disease or condition improves the efficacy of inter-
ventions to prevent or treat other conditions.
This article discusses how the limitations of health eco-
nomics reinforce the errors caused by a simplistic theory
of HIV causation and artificially isolate AIDS program-
ming from other health-promotion priorities. It suggests
better integration of complex models of epidemiology
with economic models of increasing returns to develop
more effective AIDS interventions through a broader
health-systems approach.
Although HIV is sexually transmitted in probably the major-
ity of cases in poor populations in developing countries,
exclusive focus on the proximate cause of infection (sexual
contact) does not provide an explanation for the divergence
in incidence among populations. Sexual behaviour, of
course, is important in determining individual risk, but dif-
ferences in sexual behaviour between countries do not corre-
late with differences in HIV prevalence or incidence.
Numerous empirical studies demonstrate that rich countries
have higher rates of most risky behaviours – early initiation
of sex, short-term concurrent relationships, unprotected sex,
multiple partners and premarital sex – that are not matched
by high rates of HIV [1-11]. Long-term concurrent relation-
ships may be more common in parts of sub-Saharan Africa
[12,13], but national rates of concurrency do not correlate
with rates of HIV [14].
Without coinfections or other conditions that raise per-
contact transmission rates, there is no evidence that Afri-
can concurrency or networks are more risky than sexual
networks elsewhere. The appropriate comparison for
Africa is not with a hypothetical case of no sexual net-
works, but with real sexual networks, such as are reported
on North American university campuses, with extensive
short-term concurrency and high rates of sexually trans-
mitted infections (STIs) [3,6,9], and yet low rates of HIV.
Prevention policy for HIV/AIDS is not evidence-based. In
spite of accumulating survey evidence that national or
regional rates of HIV do not correlate with rates of risky
behaviours [1,15,16], AIDS policy still emphasizes sexual
behaviour to the exclusion of other factors that influence
individual and national vulnerability to HIV. To devise
effective prevention strategies, we need to understand why
HIV spreads at different rates in different populations.
What is driving the spread of HIV in poor 
populations?
A growing body of scientific literature demonstrates that
host and ecological factors play an important role in
determining an individual's vulnerability to HIV infection
and the contagiousness of HIV-infected partners (and
mothers). Sexual contact with an infected person repre-
sents only a necessary, but not sufficient, condition for
infection through sex. Similarly, being born to an HIV-
infected mother does not always lead to infection of the
infant. Vertical transmission, before introduction of
maternal prophylaxis, ranged from 14% of infants of HIV-
infected mothers in Europe to 40% in sub-Saharan Africa
[17].
Moreover, in the absence of other factors, transmission of
HIV in industrialized countries has been insufficient to
maintain a heterosexual epidemic. In the United States
and western Europe, among otherwise healthy adults,
transmission from females to males will occur in about
one out of 1000 contacts, and from males to females,
about once in 500 contacts [17]. Clearly, other factors
play a role in determining individual infection and diver-
gence in incidence of HIV in different regions.
In the 1990s, STIs were recognized as potential cofactors
for HIV transmission, and STI treatment has been
included in some HIV-prevention programmes [18].
Some skeptics cite the Rakai trial [19], which did not seem
to confirm the role of STIs in HIV transmission, but that
trial had serious flaws, including the absence of a true con-
trol group. Rakai's "control" group was treated with
deworming medication and a vitamin/mineral supple-
ment, with results not significantly different from treating
STIs. (For additional discussion and sources, see [5].)
Later it was recognized that antiretroviral therapy (ART),
by reducing viral load, could reduce transmission [20].
More recently, male circumcision has been added to pre-
vention programmes. But AIDS policy does not yet
address the widespread nutritional, parasitic and infec-
tious conditions that can act as cofactors of HIV transmis-
sion. The following section discusses prevalence of
cofactors primarily in sub-Saharan Africa because HIV is
much higher there than elsewhere. The divergence in HIV
epidemics in different world regions suggests a complex
etiology for generalized epidemics and the need for sys-
temic solutions that solve multiple problems simultane-
ously.
Nutritional deficiencies
From 1988 to 1998, when nascent or concentrated AIDS
epidemics developed into generalized epidemics in sub-
Saharan Africa, 30% of the population of the region was
malnourished [21]. Malnutrition increases vulnerability
to infectious and parasitic diseases generally, and it
increases HIV viral load and viral shedding, thereby
increasing sexual and vertical transmission of HIV [5,22-
30].
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Malaria
More than 90% of acute malaria infections worldwide
occur in tropical Africa. Africa accounts for the majority of
malaria deaths, including about 3000 deaths per day of
children under the age of five. Survivors suffer chronic
immune activation through repeated reinfection, increas-
ing individual susceptibility of HIV-negative persons [31].
Malaria increases HIV viral load as much as 10-fold,
increasing contagiousness of HIV-infected persons and
affecting the dynamics of the epidemic at the population
level [5,32-37]. Individuals in malaria-endemic areas have
a higher probability of sexual contact with persons who
are infected with both malaria and HIV, and who thus
have high viral load. Models of malaria-HIV interaction
estimate a three-fold increase in HIV transmission in
malaria-endemic populations and increased malaria
transmission due to HIV coinfection [32].
Filariasis and geohelminthes
Lymphatic filariasis afflicts over 40 million people in sub-
Saharan Africa. Prevalence is increasing in Africa because
breeding areas for mosquitoes proliferate with unplanned
urban growth [38]. Helminthic infections (various kinds
of worms) are widespread in developing countries and
virtually ubiquitous in shanty towns and rural communi-
ties. Worldwide, nearly 1.5 billion people are infected
with ascariasis, 1.3 billion with hookworm, and more
than 1 billion with trichuriasis [39]. Lymphatic filariasis
and soil-transmitted helminthes have also been shown to
suppress immune response in HIV-negative persons and
increase viral load in HIV-infected persons, affecting indi-
vidual transmission and population dynamics [5,39-44].
A recent double-blind, controlled trial found that treating
ascariasis in HIV-infected persons results in a statistically
significant increase in CD4 counts [45]. That suggests that
a simple, inexpensive (2 US cents) and effective deworm-
ing medication (albendazole) could allow HIV-infected
people to postpone ART. On an individual and popula-
tion basis, the benefits of postponing first-line ART are
substantial.
Schistosomiasis
Urinary schistosomiasis (S. hematobium) afflicts almost
200 million people in sub-Saharan Africa [46] and acts as
a co-factor of HIV transmission in much the same way as
do STIs. Acquired in contaminated lakes and streams,
worms and ova of S. hematobium infect the reproductive
tracts of both men and women. They create lesions, which
are open portals for HIV, and inflammation of the genital
area, which makes HIV transmission more efficient [5,47-
50]. In Zimbabwe, researchers found that genital lesions
of schistosomiasis increased HIV risk in women three-fold
compared to women in the same communities without
genital schistosomiasis [51]. Furthermore, reports from
developing countries indicate that neglecting to treat
schistosomiasis, worms and malaria contributes to failure
of ART.
As we acquire new information about HIV transmission,
we have to make sure we are asking the right questions in
each regional context. Viral load is an important factor in
determining the risk of infection [52], and recent studies
have concluded that the majority of new infections are
transmitted by persons who were themselves recently
infected and thus have high viral load [53]. That is proba-
bly true in poor populations as well.
In coinfected persons in poor populations, however, the
burden of malnutrition, parasites and infectious diseases
also increases viral load, not just within the first weeks of
HIV infection, but over the lifetime of the infected person.
Malarial episodes, for example, increase viral load not just
during febrile periods, but for seven weeks afterwards
[32,36,54] and people in endemic zones are repeatedly
infected.
We can expect to see a flurry of studies on how best to
reach newly infected persons with elevated viral load. That
will be very useful, of course, but we also need to consider
the extended periods of elevated viral load in persons with
malaria and other coinfections.
In light of the conventional epidemiological understand-
ing of disease synergies and the evidence that interactions
with specific parasites and infections increase vulnerabil-
ity to and contagiousness of HIV, the exclusively behav-
ioural focus of AIDS policy reveals a very simplistic notion
of disease causation.
Limitations of the behavioural paradigm
The primary focus of HIV-prevention policy and the prin-
cipal targets of spending continue to be various strategies
for changing sexual behaviour. Substantial money and
effort have been expended, thus far without success, on
vaccine and microbicide development, but those efforts
also reflect a focus on proximate cause.
That the major political debates on AIDS policy have
revolved around promoting abstinence or providing con-
doms attests to the behavioural focus of HIV-prevention
policy. Comprehensive lists of standard interventions [55-
57] name various behaviour-change strategies for sexual
and needle-sharing behaviour and strategies for reducing
mother-to-child transmission. The additions of STI treat-
ment and male circumcision may be important steps, but
AIDS programming is still restricted to factors fairly obvi-
ously connected to a proximate cause, sexual contact.
While AIDS discourse does address social and economic
factors, such as stigma, gender roles and poverty, it is only
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to the extent that such factors influence risky sexual
behaviours, closing off other useful lines of inquiry. Gen-
der analysis of AIDS includes important issues, such as
violence and inheritance practices, but not the mundane
risks of gendered household tasks, such as washing
clothes or gathering reeds in rivers and lakes, which affect
susceptibility to HIV through genital lesions of schisto-
somiasis [58].
Studies of higher HIV prevalence among fisherfolk and
carwashers (who work standing in lake water) presume
unobserved sexual networks at the lakeshore. They fail to
consider that people who work in fresh water in Africa
have high rates of schistosomiasis, which increases HIV
transmission. We cannot examine AIDS in a laboratory
where social and economic factors affect only sexual
behaviour. People have sex and bear children in a context
of everyday risks – disease vectors, contaminated water,
food insecurity and job hazards – that make every sexual
contact and every birth more risky in poor countries.
The standard model of HIV in policy documents
In the policy literature, HIV-prevention interventions are
justified on the basis of an extremely simplistic model of
HIV transmission. The standard models for sexual trans-
mission of HIV used by multilateral and bilateral donors
(for example, AVERT, GOALS and STDSIM [59-61]) do
not incorporate what is known about the complexity of
HIV transmission. They usually assume a universal dose-
response, given in a constant per-contact transmission
risk. The core of the standard model is as follows:
where I is probability of sexual infection, N is the number
of partners, P is the prevalence rate in the population, and
T is the per-contact transmission risk, which is assumed to
be the same for every population.
Each of the models is different, but the core variables
included in each can be represented with this simple
equation. AVERT includes number of sex partners,
number of sex acts, prevalence of STIs, condom use and
related variables. GOALS includes various behaviour-
change interventions and can include blood-safety inter-
ventions.
Because the models include only population characteris-
tics related to sexual behaviour or sexual health, they
explain incidence of infection through the behavioural
variable, N, or number of partners. In circular fashion, the
only policy conclusions that derive from this equation
favour behavioural interventions. STDSIM, for example,
could incorporate schistosomiasis along with STIs, but it
does not. Omitting cofactors leads to biased estimations.
STDSIM was used to evaluate whether rates of male cir-
cumcision could explain the differences in rates of HIV in
the Four Cities Study [15], allowing for variation in other
risk factors, such as frequenting commercial sex workers.
The model was successfully fitted to the data, except for
the case of Kisumu, Kenya, leading the authors to reject
the behavioural data the men reported. Had they included
prevalence of schistosomiasis for Kisumu, which is on
Lake Victoria, their model might have predicted HIV in
Kisumu better, and they would not have had to conclude
that the men were lying about their sexual behaviour [62].
The implicit assumption underlying these models and
most HIV-prevention strategies is that differences in sex-
ual behaviour, represented by N, explain differences in
HIV rates, although the preponderance of evidence shows
no correlation at the country level between rates of vari-
ous sexual behaviours and rates of HIV.
P, prevalence, is a misleadingly simple concept. Transmis-
sion dynamics are influenced not just by the proportion of
the population that is HIV-infected, but by the infectious-
ness of each person infected. P, thus, should not be a
number, but an array of numbers representing the propor-
tion of the population infected at each level of viral load.
It matters a great deal at the individual and at the popula-
tion level what the population viral load is.
In this equation, prevalence, P, represents the probability
of a sexual contact being HIV infected. But what matters
more is the probability that a random sexual partner from
that population has a viral load above the level at which
transmission is likely to occur [52,63]. Consequently, our
understanding of the spread of HIV, in sub-Saharan Africa
in particular, would be improved if we estimated P as an
array disaggregated by level of viral load. And our preven-
tion of transmission would be enhanced by interventions
that reduce viral load in infected partners and mothers.
Transmission risk, T, should include per-contact risk of
infection for the HIV-negative person (vulnerability) and
per-contact risk of transmission for the HIV-infected per-
son (contagiousness). Both vulnerability and contagious-
ness could be increased by infection with helminthes,
malaria, malnutrition, tuberculosis, STIs and schisto-
somiasis. (To avoid double-counting the enhanced conta-
giousness of the HIV-infected person, we would include
here only factors not captured in the estimate of viral load
in the array of P. Genital sores of schistosomiasis or STIs
in either partner would be included here, for example.)
Similarly, a new model for vertical transmission should
include characteristics of mother and infant, including
anemia and other nutritional deficiencies, geohelminth
exposure, schistosomiasis and STIs. Epidemic models for
I N P T= ´ ´
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poor countries should also include primary transmission
by contaminated medical instruments and blood. Even if
such medical transmission produces only the 5% to 10%
of primary infections conservatively estimated by
UNAIDS [64], that is an underestimated source of primary
infection for women and infants in particular, since both
are more likely to undergo invasive medical procedures
than are men [65,66].
The standard model, with a scalar P and a constant T,
assumes that one risk fits all individuals and all popula-
tions, abstracting from almost all the important biological
variation between rich and poor, and temperate and trop-
ical populations. Modifying P and T helps, but it does not
begin to model the complex interactions among condi-
tions or to estimate the effect of non-linearities in the
impact of one or more conditions on others. We would
need more fully specified models to do that, although it
may not be possible or mathematically meaningful to
aggregate all conditions across all individuals.
The point is that if we use a model that assumes one risk
fits all, as do most models used in AIDS policy, we cannot
explain the global distribution of HIV and AIDS, and we
cannot generate useful prevention policies for different
regions. By cataloguing all the endemic conditions that
are known to influence the spread of HIV in poor popula-
tions, and accounting for the disease synergies, we can
attempt to design HIV programmes that address the differ-
ential risk of multi-burdened populations.
That does not, however, mean that we should postpone
treatment for widespread, debilitating conditions until we
have the perfect model. We already have plenty of evi-
dence that treating STIs, helminthes, malaria and malnu-
trition are good things in themselves. The only barriers to
addressing those problems have been a lack of political
will and flawed economic models.
Complexity and HIV
We need new ways of thinking about HIV causation, and
here, I outline one way to begin. The AIDS epidemic, like
most epidemics, is a complex, contingent process. In com-
plex adaptive (or contingent) systems, even small differ-
ences in initial conditions can result in widely different
outcomes, and sudden or rapid change can produce bifur-
cations, or changes in trajectory. Edward Lorenz observed
such results in the 1960s, when his modelling of weather
conditions calculated at three decimal places produced
widely different forecasts from his calculations at seven
decimal places [67].
As epidemics unfold as complex, contingent processes,
both the exposures (sexual contacts for HIV) and the
infections themselves result from multiple, interacting
causes. Sequential iterations produce new trajectories that
are determined (not random), but unpredictable at the
outset. In different countries and different regions, rele-
vant conditions of hosts, environment and sometimes the
pathogen can differ not just by small amounts, but by sev-
eral orders of magnitude.
In the United States and Europe, for example, malaria and
schistosomiasis are extremely rare, whereas in Africa the
number of malaria cases per year exceeds 25% of the pop-
ulation in 27 countries [68] and the number of schisto-
somiasis cases exceeds 25% of the population in 22
countries [69]. Differences in the burden of other parasitic
diseases are similarly vast.
It is simplistic to assume that a large event, such as a gen-
eralized HIV epidemic, results from a single large cause, a
lone gunman. It is more likely that large events are the
result of the synergistic effect of multiple causes, each of
which may show slight variation between regions. The
divergence in HIV incidence between rich and poor coun-
tries and between temperate and tropical areas is affected
by the interplay of malaria, STIs, helminthes, filariases,
anemia, vitamin-A deficiency and many other factors, for
which the differences between rich and poor populations
are great.
Moreover, even between western and southern Africa, the
relative weights of each of those factors differ, although
they are not differences in order of magnitude. As in
weather patterns, it is quite plausible that very small dif-
ferences in initial conditions of one or several factors can
result in very different outcomes in incidence of diseases
with multiple, interacting determinants.
Boolean networks
One way to visualize how AIDS epidemics behave as com-
plex systems with interacting variables is to use Boolean
networks, employed by some biologists [70]. In a system
with N elements (for example, diseases or environmental
factors), some of those elements interact and are called
inputs, designated as K. In simple systems, of K = 2 or K =
3, stable outcomes can be expected. When every variable
is connected to every other variable – a so-called K = N
network – outcomes are said to be completely random
[70,71], although perhaps it should be said that they are
determined but unpredictable.
A Boolean network seems to model HIV effectively. In
developed countries, it may be that K = 2 or K = 3, and
incidence would therefore be stable and predictable; this
has generally been the case in western Europe and North
America. In poor populations in tropical regions, with
many interacting variables (malaria, malnutrition,
worms, etc.), K approaches N, and epidemics are unstable
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and unpredictable. The greater the number of factors, the
more sensitive are the outcomes (epidemic trajectories) to
initial conditions.
As Kauffman observed in reference to other K = N systems,
minimal changes typically cause extensive damage – alter-
ations in the activity patterns – almost immediately [70]
(p. 81). This approach might be extremely useful when
applied to HIV, considering the divergent evolutions of
HIV epidemics in different populations. No other credible
explanation has been offered for the near-explosive
growth of HIV in southern Africa. And no single variable
can explain the differences between regions, be it male cir-
cumcision, labour migration patterns, local sexual prac-
tices or parasite burden.
Clearly, if K = N or nearly so, policy makers must work
with a reduced form of the model. They have to choose
the most significant coinfections for interventions. But to
make policy that is relevant to a real-world epidemic, and
even to recognize the most significant coinfections, they
need to bear in mind that such complex interactions of
multiple factors determine the diverging trajectories in
different regions.
The good news is that while disease interactions can accel-
erate epidemics, they also provide multiple entry points to
interrupt transmission. Many of those opportunities, such
as providing clean water and sanitation and deworming,
are much more policy sensitive than sexual behaviour,
and they have multiple beneficial effects.
The poverty of economics
Ignoring interacting and multiple-level variables has gen-
erated an inadequate theory of disease causation to
inform AIDS policy. That problem is reinforced because of
the limitations of health economics, and cost-effective-
ness analysis in particular, in evaluating complex inter-
ventions. Unlike other fields of economics, health
economics has not been drawn into the exploration of
complexity, non-linearity and multiple equilibria.
Since disease interactions have non-linear effects, multi-
ple outcomes are not only possible, but quite likely in dis-
ease dynamics. But recognition of non-linearities is rare in
health economics. (In a search of all articles published in
Health Economics, Health Policy and Planning, and Journal of
Health Economics in the past 10 years, I found only three
articles that made any reference to interaction variables or
non-linearities. None was based on a model of biological
interaction.)
Clearly, policy makers must employ some method of eval-
uating interventions, and the principle of cost-effective-
ness analysis is valid. Cost-effectiveness analysis, however,
is best used when there are identical outcomes to alterna-
tive treatments or when it is easy to measure a single
objective (outcome) of the intervention [72].
In an epidemic with multiple, interacting causes, it is dif-
ficult to define interventions with identical outcomes or
to evaluate treatments with only one kind of benefit. The
use of simple cost-effectiveness analysis appears to vali-
date the superiority of single-input interventions because,
as it is currently employed, it cannot measure the benefits
of programmes with heterogeneous or diffuse benefits,
unanticipated spillover benefits, or benefits that take
some time to appear. With few notable exceptions [73],
they fail to recognize increasing returns (decreasing costs)
or other non-linearities in interventions.
Increasing returns: economics in the real world
The general equilibrium model that has dominated eco-
nomics for more than a century assumes negative feed-
backs (decreasing returns) that lead to a unique, stable
equilibrium under perfect competition.
Since the 1980s, economists have attempted to model
positive feedbacks in growth theory, trade theory and
other fields [74-77]. Positive feedbacks (increasing
returns) generally provide a better description of actual
economic conditions, especially of the past 200 years.
They do not lead to a unique, stable equilibrium (are not
boundary defending), but instead can have multiple pos-
sible outcomes (misleadingly called equilibria). Health
economics, however, is based on the conventional eco-
nomic model of the early twentieth century that assumes
decreasing or constant returns (increasing or constant
costs), although that is rarely stated explicitly.
Increasing returns can occur for various reasons. The sim-
plest case is that of scale economies, where the fixed costs
of a clinic, for example, are spread over a larger number of
patients, and the marginal cost of additional patients is
negligible. A second type is economies of scope, where
fixed costs are spread over more services, and additional
services are virtually costless. Where economies of scope
are present, modelling a number of services together
would give more valid estimates of cost effectiveness than
requiring each service to be justified independently, as is
more generally the case in cost-effectiveness analysis.
Health economists tend to focus on short-run diminish-
ing returns, rather than scale economies, and belabour the
increasing cost of bringing treatment to ever more remote
villages. But that is generally not the situation in the field.
In reality, tens of thousands of people in poor countries
with generalized HIV epidemics die without any treat-
ment even though they live in close proximity to health
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facilities. Reaching them does not entail rising costs per
person. Many clinics can still expand the range of services
and the number of people served with decreasing average
cost. As word spreads about ART and treatment of coinfec-
tions, such as ascariasis, schistosomiasis and malaria, out-
reach can be self-sustaining. And as the number of people
receiving treatment grows, there are also population ben-
efits (herd effects) for both prevention and treatment,
which lower future costs.
Cost-effectiveness analysis and health economics gener-
ally would be more useful if they incorporated more
health information. They need to be interdisciplinary,
using economic tools but reflecting the underlying biolog-
ical complexity of conditions they hope to address. To
integrate the economics and the biology, I would add to
the conventional economic notions of economies of scale
and scope two categories of biologically based increasing
returns arising from disease interactions.
One is the positive treatment spillover within the individ-
ual. For example, treatment for cofactor conditions,
including worms, malnutrition and malaria, makes HIV
prevention and ART more effective for each individual.
The second biologically driven cause of increasing returns
is the population effect. Treatment for HIV, helminthes,
TB and malaria (among other things) reduces transmis-
sion in the population by reducing HIV viral load, parasite
burden and infectiousness of TB.
To calculate accurately the costs of delivering services for
a population, we have to include the population spillo-
vers (benefits) that reduce viral load, transmission, and
subsequent costs of prevention and treatment. If we do
not calculate conventional economies of scale and scope
and intra-individual treatment benefits (such as deworm-
ing for HIV) and externalities (population effects), we seri-
ously underestimate the benefits of complementary
interventions, and we allocate resources improperly. Ulti-
mately, we need to broaden the scope of what we consider
treatment outcomes in calculating benefits of pro-
grammes that affect multiple sectors. Deworming, for
example, not only improves health, it also improves
school attendance and cognitive development, but a
health sector evaluation might not include those benefits.
The result of using simplistic cost-effectiveness analysis
that can compare only very similar interventions is that
the tool can identify only local maxima (minima). But the
landscape of HIV transmission is very complex. If we only
want to advise policy makers on whether it is better to
hand out condoms in a community centre or in a factory,
or hand out condoms with or without lollipops as an
inducement, the current methods are adequate. If, how-
ever, we want to reduce the significant relative risks in
poor environments (compared to rich environments),
those risk factors must be included in the models, and the
benefits of complementary interventions have to be calcu-
lated.
The generation of local maxima is essentially a Type III
error – we get very precise, and even correct, answers to the
wrong questions [78]. But it will not matter very much if
one approach to condom distribution is marginally better
than another if the larger reason that HIV spreads so rap-
idly in poor populations is the prevalence of endemic par-
asitic and infectious diseases.
Conclusion
HIV epidemics, like other complex systems, are influenced
by multiple factors. The issue is not that sexual behaviour
is unimportant. It is that behaviour explains so little about
why poor people get sick, especially in tropical areas with
little access to safe medical care, clean water, sanitation
and good housing to protect them from disease vectors.
Standard HIV-prevention policies, and thus cost-effective-
ness analyses evaluating those interventions, have over-
looked complementary investments for treating
coinfections. Treatment for TB, schistosomiasis, malaria,
malnutrition and helminthes is relatively inexpensive,
highly effective, and essential for improving immune sta-
tus in HIV-negative persons and decreasing viral load in
HIV-infected persons.
Such investments are not a diversion of funds from HIV
prevention; they are necessary complements. Deworming
is safe, effective and easily dosed; it generates positive
externalities [79]; and it might also prevent the failure of
first-line ART – at a cost of as little as 2 US cents per per-
son. The cost of moving to second-line therapy will far
exceed the cost of treating coinfections.
We need cost-effectiveness tools that reflect complexity
and attempt to measure the costs of multiple inputs dis-
tributed over multiple outputs in which interactions play
a prominent role. Those tools would recognize conven-
tional economies of scale and scope, which are extensive
in multi-purpose programmes, as well as biological exter-
nalities, both intra-individual and population-wide, that,
if exploited, reduce overall cost. With those tools, we can
achieve our goal of healthy individuals in healthy popula-
tions, rather than chasing after one virus, one person at a
time.
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